Chief executive of Turing Pharmaceuticals Martin Shkreli was met with widespread outrage after his decision to increase the price of the 62-year-old toxoplasmosis treatment Daraprim (pyrimethamine) from US$13.50 to US$750 per pill shortly after acquiring the drug from Impax Laboratories in August 2015. Shkreli has said he will provide the drug for free to patients unable to afford it - he says the company give away 50% of Daraprim bottles for US$1 or less. He has also said that a portion of any profits will be used for vital research into toxoplasmosis, a rare parasitic infection, potentially fatal for immunocompromised patients. However, his controversial decision and initial hostility in media interactions led to a barrage of insults levelled against him, including "the most despised man in America", "scumbag" and "spoiled brat".
展开▼
